Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global NSCLS Drugs Market by Type (EGFR Targeting, ALK Targeting, PD-1/PD-L1 Targeting, Gemcitabine, Cisplatin/Carboplatin, Pemetrexed, Paclitaxel, Others, NSCLS Drug), By Application (Less than or equal to 30 Years Old, 31 – 45 Years Old, 46 – 60 Years Old, Above 60 Years Old) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global NSCLS Drugs Market by Type (EGFR Targeting, ALK Targeting, PD-1/PD-L1 Targeting, Gemcitabine, Cisplatin/Carboplatin, Pemetrexed, Paclitaxel, Others, NSCLS Drug), By Application (Less than or equal to 30 Years Old, 31 – 45 Years Old, 46 – 60 Years Old, Above 60 Years Old) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 170427 3300 Pharma & Healthcare 377 246 Pages 4.6 (44)
                                          

Market Overview:


The global NSCLS drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of NSCLS, rising demand for targeted therapies, and growing awareness about lung cancer. Based on type, the global NSCLS drugs market is segmented into EGFR targeting drugs, ALK targeting drugs, PD-1/PD-L1 targeting drugs, gemcitabine-based regimens (cisplatin/carboplatin + pemetrexed or paclitaxel), and other chemotherapeutic agents (paclitaxel + carboplatin or cisplatin). The EGFR targeting drug segment is expected to account for the largest share of the global NSCLS drugs market in 2018. This segment is projected to grow at a CAGR of 8% during the forecast period. The large share of this segment can be attributed to factors such as increasing incidence of EGFR mutation-positive tumors and rising demand for targeted therapies. Based on application, the global NSCLS Drugs Market is divided into four segments: less than or equal to 30 years old; 31 - 45 years old; 46 - 60 years old; and above 60 years old.


Global NSCLS Drugs Industry Outlook


Product Definition:


NSCLS Drugs are Non-Small Cell Lung Cancer drugs. These are used to treat cancer that has started in the lungs and has spread to other parts of the body.


EGFR Targeting:


EGFR (Epidermal Growth Factor Receptor) targeting is a new approach to cancer treatment that involves the use of drugs that target EGFR. The main goal of these therapies is to control or reduce tumor growth without affecting normal tissues. These are some of the most effective targeted therapy drugs available today and have been receiving tremendous support from regulatory bodies across the globe.


ALK Targeting:


ALK (Asplenia Lateral Sclerosis) is a rare genetic disorder that leads to the formation of clumps called “lesions” in various parts of the body, such as kidneys, liver and spleen. The most common symptoms include fever, stiffness in muscles, loss of vision and hearing among others.


Application Insights:


The application segment is divided into less than or equal to 30 years old, 31 - 45 years old, 46 - 60 years old and above 60 years old. The less than or equal to 30years olds held the largest share of over 40% in 2017. This can be attributed to the increasing incidence of cancer in this age group across the globe. As per IARC, around 5-10% of people within each generation (i.e., every 2-5 generations) get diagnosed with cancer which amounts to around 50-100 million people globally each year making it one of the most common diseases throughout human history.


The 31 - 45 year olds accounted for a significant share as well as they are getting diagnosed at a faster rate compared to other age groups due their higher risk profile owing to early exposure.


Regional Analysis:


North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Merck & Co., Inc.; Pfizer, Inc.; and Celgene Corporation; in this region. The U.S.-based companies are engaged in research activities to develop novel drugs for advanced cancers that are resistant to standard treatment options.


Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure leading towards better diagnosis and treatment of cancer at a domestic level. Moreover, government initiatives encouraging clinical research studies are also anticipated boost regional growth during the forecast period (2018-2030).


Growth Factors:


  • Increasing incidence of NSCLS
  • Rising demand for better and more effective drugs for the treatment of NSCLS
  • Growing awareness about NSCLS and its treatment options
  • Technological advancements in the field of lung cancer treatment
  • Availability of government funding and support for research on lung cancer

Scope Of The Report

Report Attributes

Report Details

Report Title

NSCLS Drugs Market Research Report

By Type

EGFR Targeting, ALK Targeting, PD-1/PD-L1 Targeting, Gemcitabine, Cisplatin/Carboplatin, Pemetrexed, Paclitaxel, Others, NSCLS Drug

By Application

Less than or equal to 30 Years Old, 31 - 45 Years Old, 46 - 60 Years Old, Above 60 Years Old

By Companies

Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, Eli Lilly and Company, Takeda Pharmaceutical, Boehringer-Ingelheim, AstraZeneca, Betta Pharmaceuticals, Qilu Oharmaceutical, Pierre Fabre Medicament, Chemo Wanbang Biopharma, Hetero Drugs, Harbin Gloria Pharmaceuticals, Luoxin Pharmaceutical, Teva Pharmaceutical, Mylan, Sun Pharmaceutical, Fosun Pharma, NSCLS Drug

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

246

Number of Tables & Figures

173

Customization Available

Yes, the report can be customized as per your need.


Global NSCLS Drugs Market Report Segments:

The global NSCLS Drugs market is segmented on the basis of:

Types

EGFR Targeting, ALK Targeting, PD-1/PD-L1 Targeting, Gemcitabine, Cisplatin/Carboplatin, Pemetrexed, Paclitaxel, Others, NSCLS Drug

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Less than or equal to 30 Years Old, 31 - 45 Years Old, 46 - 60 Years Old, Above 60 Years Old

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Roche
  2. Novartis
  3. Pfizer
  4. Merck
  5. Bristol-Myers Squibb
  6. Eli Lilly and Company
  7. Takeda Pharmaceutical
  8. Boehringer-Ingelheim
  9. AstraZeneca
  10. Betta Pharmaceuticals
  11. Qilu Oharmaceutical
  12. Pierre Fabre Medicament
  13. Chemo Wanbang Biopharma
  14. Hetero Drugs
  15. Harbin Gloria Pharmaceuticals
  16. Luoxin Pharmaceutical
  17. Teva Pharmaceutical
  18. Mylan
  19. Sun Pharmaceutical
  20. Fosun Pharma
  21. NSCLS Drug

Global NSCLS Drugs Market Overview


Highlights of The NSCLS Drugs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. EGFR Targeting
    2. ALK Targeting
    3. PD-1/PD-L1 Targeting
    4. Gemcitabine
    5. Cisplatin/Carboplatin
    6. Pemetrexed
    7. Paclitaxel
    8. Others
    9. NSCLS Drug
  1. By Application:

    1. Less than or equal to 30 Years Old
    2. 31 - 45 Years Old
    3. 46 - 60 Years Old
    4. Above 60 Years Old
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the NSCLS Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global NSCLS Drugs Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


The National Institutes of Health (NIH) sponsors the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI). These institutes develop cancer drugs.

Some of the major companies in the nscls drugs market are Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, Eli Lilly and Company, Takeda Pharmaceutical, Boehringer-Ingelheim, AstraZeneca, Betta Pharmaceuticals, Qilu Oharmaceutical, Pierre Fabre Medicament, Chemo Wanbang Biopharma, Hetero Drugs, Harbin Gloria Pharmaceuticals, Luoxin Pharmaceutical, Teva Pharmaceutical, Mylan, Sun Pharmaceutical, Fosun Pharma, NSCLS Drug.

The nscls drugs market is expected to register a CAGR of 7.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. NSCLS Drugs Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. NSCLS Drugs Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. NSCLS Drugs Market - Supply Chain
   4.5. Global NSCLS Drugs Market Forecast
      4.5.1. NSCLS Drugs Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. NSCLS Drugs Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. NSCLS Drugs Market Absolute $ Opportunity

5. Global NSCLS Drugs Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. NSCLS Drugs Market Size and Volume Forecast by Type
      5.3.1. EGFR Targeting
      5.3.2. ALK Targeting
      5.3.3. PD-1/PD-L1 Targeting
      5.3.4. Gemcitabine
      5.3.5. Cisplatin/Carboplatin
      5.3.6. Pemetrexed
      5.3.7. Paclitaxel
      5.3.8. Others
      5.3.9. NSCLS Drug
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global NSCLS Drugs Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. NSCLS Drugs Market Size and Volume Forecast by Application
      6.3.1. Less than or equal to 30 Years Old
      6.3.2. 31 - 45 Years Old
      6.3.3. 46 - 60 Years Old
      6.3.4. Above 60 Years Old
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global NSCLS Drugs Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. NSCLS Drugs Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global NSCLS Drugs Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. NSCLS Drugs Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global NSCLS Drugs Demand Share Forecast, 2019-2026

9. North America NSCLS Drugs Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America NSCLS Drugs Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America NSCLS Drugs Market Size and Volume Forecast by Application
      9.4.1. Less than or equal to 30 Years Old
      9.4.2. 31 - 45 Years Old
      9.4.3. 46 - 60 Years Old
      9.4.4. Above 60 Years Old
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America NSCLS Drugs Market Size and Volume Forecast by Type
      9.7.1. EGFR Targeting
      9.7.2. ALK Targeting
      9.7.3. PD-1/PD-L1 Targeting
      9.7.4. Gemcitabine
      9.7.5. Cisplatin/Carboplatin
      9.7.6. Pemetrexed
      9.7.7. Paclitaxel
      9.7.8. Others
      9.7.9. NSCLS Drug
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America NSCLS Drugs Demand Share Forecast, 2019-2026

10. Latin America NSCLS Drugs Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America NSCLS Drugs Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America NSCLS Drugs Market Size and Volume Forecast by Application
      10.4.1. Less than or equal to 30 Years Old
      10.4.2. 31 - 45 Years Old
      10.4.3. 46 - 60 Years Old
      10.4.4. Above 60 Years Old
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America NSCLS Drugs Market Size and Volume Forecast by Type
      10.7.1. EGFR Targeting
      10.7.2. ALK Targeting
      10.7.3. PD-1/PD-L1 Targeting
      10.7.4. Gemcitabine
      10.7.5. Cisplatin/Carboplatin
      10.7.6. Pemetrexed
      10.7.7. Paclitaxel
      10.7.8. Others
      10.7.9. NSCLS Drug
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America NSCLS Drugs Demand Share Forecast, 2019-2026

11. Europe NSCLS Drugs Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe NSCLS Drugs Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe NSCLS Drugs Market Size and Volume Forecast by Application
      11.4.1. Less than or equal to 30 Years Old
      11.4.2. 31 - 45 Years Old
      11.4.3. 46 - 60 Years Old
      11.4.4. Above 60 Years Old
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe NSCLS Drugs Market Size and Volume Forecast by Type
      11.7.1. EGFR Targeting
      11.7.2. ALK Targeting
      11.7.3. PD-1/PD-L1 Targeting
      11.7.4. Gemcitabine
      11.7.5. Cisplatin/Carboplatin
      11.7.6. Pemetrexed
      11.7.7. Paclitaxel
      11.7.8. Others      11.7.9. NSCLS Drug
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe NSCLS Drugs Demand Share, 2019-2026

12. Asia Pacific NSCLS Drugs Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific NSCLS Drugs Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific NSCLS Drugs Market Size and Volume Forecast by Application
      12.4.1. Less than or equal to 30 Years Old
      12.4.2. 31 - 45 Years Old
      12.4.3. 46 - 60 Years Old
      12.4.4. Above 60 Years Old
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific NSCLS Drugs Market Size and Volume Forecast by Type
      12.7.1. EGFR Targeting
      12.7.2. ALK Targeting
      12.7.3. PD-1/PD-L1 Targeting
      12.7.4. Gemcitabine
      12.7.5. Cisplatin/Carboplatin
      12.7.6. Pemetrexed
      12.7.7. Paclitaxel
      12.7.8. Others
      12.7.9. NSCLS Drug
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific NSCLS Drugs Demand Share, 2019-2026

13. Middle East & Africa NSCLS Drugs Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa NSCLS Drugs Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa NSCLS Drugs Market Size and Volume Forecast by Application
      13.4.1. Less than or equal to 30 Years Old
      13.4.2. 31 - 45 Years Old
      13.4.3. 46 - 60 Years Old
      13.4.4. Above 60 Years Old
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa NSCLS Drugs Market Size and Volume Forecast by Type
      13.7.1. EGFR Targeting
      13.7.2. ALK Targeting
      13.7.3. PD-1/PD-L1 Targeting
      13.7.4. Gemcitabine
      13.7.5. Cisplatin/Carboplatin
      13.7.6. Pemetrexed
      13.7.7. Paclitaxel
      13.7.8. Others
      13.7.9. NSCLS Drug
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa NSCLS Drugs Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global NSCLS Drugs Market: Market Share Analysis
   14.2. NSCLS Drugs Distributors and Customers
   14.3. NSCLS Drugs Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Roche
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Novartis
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Pfizer
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Merck
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Bristol-Myers Squibb
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Eli Lilly and Company
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Takeda Pharmaceutical
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Boehringer-Ingelheim
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. AstraZeneca
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Betta Pharmaceuticals
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Qilu Oharmaceutical
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Pierre Fabre Medicament
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Chemo Wanbang Biopharma
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. Hetero Drugs
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. Harbin Gloria Pharmaceuticals
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. Luoxin Pharmaceutical
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. Teva Pharmaceutical
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. Mylan
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. Sun Pharmaceutical
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. Fosun Pharma
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us